Detailed View
IOVA - Iovance Biotherapeutics, Inc.
Latest filing: 2026-06-30 | Reporting: gaap
Market Cap
2,899,017,216
Adj EBIT (TTM)
-301,309,000
Enterprise Value
2,602,311,216
Last Price
6.40
Earnings Yield
-11.58%
Return on Capital
-55.31%
Capital
544,789,000
1Y Price Chart
Last Price: -
1Y Change: -
Company Summary
Loading summary...
| endDate | formType | fiscalYear | Revenue | OperatingIncomeLoss |
|---|---|---|---|---|
| 2026-06-30 | 10-Q | 2026 | 99,313,000 | -51,905,000 |
| 2026-03-31 | 10-Q | 2026 | 71,430,000 | -81,043,000 |
| 2025-12-31 | 10-K (Q4 derived) | 2025 | 86,771,000 | -73,460,000 |
| 2025-09-30 | 10-Q | 2025 | 67,455,000 | -94,901,000 |
| 2025-06-30 | 10-Q | 2025 | 59,952,000 | -113,774,000 |
| 2025-03-31 | 10-Q | 2025 | 49,324,000 | -121,221,000 |
| 2024-12-31 | 10-K (Q4 derived) | 2024 | 73,694,000 | -86,576,000 |
| 2024-09-30 | 10-Q | 2024 | 58,555,000 | -89,066,000 |
Notice something wrong?
Submit a quick report with a snapshot of the values you are seeing.